BCC on the face: treatment, reconstruction, and outcomes

Basal cell carcinoma on the face, known clinically as facial BCC, is the most common form of skin cancer in the United Kingdom and arises predominantly on sun-exposed skin. Up to 80% of all BCCs occur on the face, a direct consequence of cumulative lifetime ultraviolet exposure. The cancer grows slowly but causes progressive tissue destruction if left untreated. Early recognition, accurate diagnosis, and specialist-led treatment are the factors that determine both cure rates and the quality of the final cosmetic result. This article explains what to look for, how facial BCC is diagnosed and treated, and what reconstruction involves.

What does BCC on the face look like?

Facial BCC presents in several distinct forms, and recognising the differences matters because each subtype carries a different level of aggressiveness. The most common presentation is a shiny, pearly nodule with small visible blood vessels on the surface, typically appearing on the nose, cheeks, or forehead. A second pattern is a persistent ulcer that bleeds, crusts, and refuses to heal over weeks or months. A third is a flat, scar-like area with an ill-defined edge, which is the morphoeic subtype and the most deceptive of all.

The sites most frequently affected on the face are the nose, eyelids, inner corners of the eye, temples, ears, and the skin around the mouth. These are precisely the areas that receive the highest cumulative sun exposure over a lifetime. BCC lesions can closely resemble benign conditions such as eczema, psoriasis, persistent pimples, or old scars, which is why many patients delay seeking advice for months or even years.

The ABCDE rule, widely used for melanoma, has limited direct application to BCC. Dermoscopy, a technique using a handheld magnifying device with polarised light, is far more useful. A trained clinician using dermoscopy can identify the arborising blood vessels, blue-grey ovoid nests, and leaf-like structures that characterise BCC subtypes with high accuracy.

• Nodular BCC: shiny, dome-shaped, pink or flesh-coloured bump with visible blood vessels
• Superficial BCC: flat, pink or red scaly patch, often mistaken for eczema or psoriasis
• Morphoeic BCC: pale, scar-like, firm plaque with poorly defined borders; the highest-risk subtype
• Pigmented BCC: contains brown or black pigment, occasionally mistaken for melanoma

Pro Tip: Any spot on your face that has not healed within four weeks, bleeds without injury, or looks like a scar where you have had no wound deserves a specialist opinion. Do not wait for it to change further.

How is facial BCC diagnosed and classified?

Diagnosis of facial BCC follows a structured pathway that begins with clinical examination and ends with histopathological confirmation. No treatment should proceed without a tissue diagnosis.

1. Clinical examination: A specialist examines the lesion with the naked eye and dermoscopy, assessing size, borders, surface texture, and the presence of telangiectasia or pigmentation.
2. Biopsy: A punch biopsy or shave biopsy is taken under local anaesthetic. The sample is sent to a histopathologist who confirms the diagnosis and identifies the subtype.
3. Subtype classification: The histopathology report classifies the BCC as nodular, superficial, morphoeic, infiltrative, or basosquamous. This classification directly determines treatment choice.
4. Risk stratification: Lesions are categorised as low risk or high risk based on size, site, subtype, and whether the tumour is primary or recurrent.
5. Imaging: In rare aggressive cases, imaging should complement clinical assessment to determine tumour depth and guide surgical planning, particularly when bone involvement is suspected.
6. Multidisciplinary team review: Complex or recurrent cases are discussed at a skin cancer multidisciplinary team meeting, involving dermatology, plastic surgery, oncology, and radiology.

Understanding your lesion’s risk category is not a formality. It determines whether standard surgical excision is appropriate or whether Mohs micrographic surgery is the recommended approach. For a detailed overview of identifying facial BCC, the clinical features that prompt referral are well documented.

What are the treatment options for BCC on the face?

Surgical excision and Mohs micrographic surgery are the two gold-standard treatments for facial BCC. The choice between them depends on the lesion’s subtype, size, site, and whether it is a primary or recurrent tumour.

Standard surgical excision

Standard excision removes the tumour with a margin of clinically normal skin, typically 3–5 mm for low-risk lesions. The excised tissue is sent for histopathology after the procedure. If the margins are not clear, a second operation is required. This approach is appropriate for well-defined, low-risk BCCs in sites where tissue conservation is less critical.

Mohs micrographic surgery

Mohs surgery is preferred for precise excision and reconstruction planning in cosmetically sensitive facial areas. The procedure involves removing the tumour in thin layers, with each layer examined under a microscope on the same day. Removal continues only in the direction where cancer cells remain. This means healthy tissue is preserved to the maximum extent possible, which is critical on the nose, eyelids, and ears where every millimetre of skin matters. Mohs micrographic surgery involves systematic margin assessment enabling maximal tissue conservation, which is the defining advantage over standard excision for high-risk facial sites.

Radiotherapy

Radiotherapy is an effective option for patients who are medically unfit for surgery or who decline an operation. It is also used as adjuvant treatment after surgery in cases with perineural invasion. The cosmetic result with radiotherapy tends to deteriorate over years, which is a relevant consideration for younger patients.

Hedgehog pathway inhibitors

Vismodegib is a targeted oral therapy that blocks the Hedgehog signalling pathway, which drives BCC growth. It is reserved for locally advanced or metastatic BCC where surgery is not feasible. In periocular BCC, vismodegib achieves a complete response rate of approximately 38% and a partial response in a further 39% of cases. However, recurrence after stopping therapy occurs in around 17% of patients, and adverse events including muscle cramps, hair loss, and fatigue are common. Medical therapies like vismodegib represent important alternatives for patients unsuitable for surgery, but require careful counselling regarding side effects and recurrence risk.

Pro Tip: If you are offered Mohs surgery for a BCC near your eye, nose, or ear, ask specifically whether your surgeon has dual training in both Mohs and plastic surgery. The two skills together produce the best functional and cosmetic result.

Early treatment prevents deep invasion and facial tissue destruction. In rare long-standing cases, bone invasion has been documented in large tumours on the nose and forehead, requiring complex craniofacial surgery. This outcome is avoidable with timely diagnosis and treatment.

The psychosocial benefit of well-executed reconstruction is significant. Patients who achieve a good cosmetic outcome report higher confidence, reduced anxiety, and faster return to normal social activity. Realistic expectations are set before surgery: scars will be present but are designed to follow natural facial lines and fade over 12–18 months. Combining surgical precision with aesthetic expertise is the defining factor in optimising both cure and quality of life after facial BCC treatment.

Scar management after reconstruction includes silicone gel or sheeting from six weeks post-operatively, sun protection of the scar for at least 12 months, and massage once the wound is fully healed. In selected cases, laser treatment or steroid injections are used to refine the scar further.

What should patients know about monitoring and long-term care?

Treatment of facial BCC does not end at the operating table. Structured follow-up is a clinical requirement, not an optional extra.

1. Follow-up schedule: Most patients are reviewed at three months, six months, and 12 months after treatment. High-risk cases or those treated for recurrent BCC are followed for five years.
2. Recurrence recognition: 30% recurrence at five years has been reported in some series for high-risk lesions. Patients should know that a new shiny nodule, a non-healing area, or a change in the scar texture at the treatment site warrants urgent review.
3. Self-examination: Monthly self-examination of the face in good light is recommended. Use a mirror to check the nose, ears, and hairline, which are easy to overlook.
4. Sun protection: Daily broad-spectrum SPF 50 sunscreen on all exposed facial skin is the single most effective measure for preventing new BCCs. Protective clothing, hats with a brim, and avoiding midday sun between 11am and 3pm reduce cumulative UV damage further.
5. New primary BCCs: Patients who have had one BCC have a significantly elevated risk of developing further primary BCCs elsewhere on the face or body. Annual skin checks with a specialist are advised for life.
6. Lifelong dermatologic care: Patients with a history of multiple BCCs, immunosuppression, or Gorlin syndrome require more frequent surveillance and may benefit from chemoprevention strategies discussed with their specialist team.

Skin cancer prevention and recovery practices are well established and should form part of every patient’s long-term plan after facial BCC treatment.

Key takeaways

Facial BCC is highly treatable when caught early, but the choice of treatment and the quality of reconstruction determine both cure rates and long-term cosmetic outcomes.

Expert Mohs surgery and facial reconstruction at Rakhee Nayar – Mohs Surgeon and Skin Specialist

If you have been diagnosed with or are concerned about a facial BCC, specialist assessment is the right next step.

Rakhee Nayar – Mohs Surgeon and Skin Specialist offers consultant-led Mohs surgery for facial BCC at Circle Cheshire, with Miss Nayar’s unique dual training in both Mohs and plastic surgery ensuring that tumour clearance and facial reconstruction are managed by a single expert. Private consultations and e-consultations are available for UK and international patients. For patients who want to understand their lesion before booking, the skin cancer symptoms guide provides a clear starting point. To discuss your diagnosis or arrange an assessment, contact the clinic directly.

This article is for information only and does not constitute medical advice. Consult a GMC-registered specialist for assessment and treatment of any skin lesion.

FAQ

Recommended

• BCC skin cancer: causes, treatment, and recovery
• Basal cell carcinoma: Mohs surgery and facial aesthetics
• BCC skin cancer explained: diagnosis and treatment
• SCC: Diagnosis, Mohs surgery and facial reconstruction

Filed under Basal and Squamous Cell Carcinoma